CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 163 enrolled
Drug / intervention
AGN-210961 Formulation 1 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01110499
NCT01110499Phase 2Completed
CompareCT.gov

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Apr 26, 2010·Updated Aug 5, 2014

In Brief

A Phase 2 clinical trial evaluating AGN-210961 Formulation 1, AGN-210961 Formulation 2, and 6 other interventions for Ocular Hypertension and Primary Open-Angle Glaucoma. Completed, enrolled 163 participants across 1 site.

Detailed Summary

This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days. Part 2 will evaluate the safety and IOP effects of a formulation (to be selected from part 1) of AGN-210961 in both eyes compared to bimatoprost ophthalmic solution 0.03% for 4 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Primary Open-Angle Glaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 26, 2010
Enrollment StartJun 1, 2010
Primary CompletionMay 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.2 years ago

Interventions

AGN-210961 Formulation 1drug

AGN-210961 Formulation 1 in one eye once daily for 7 days.

AGN-210961 Formulation 2drug

AGN-210961 Formulation 2 in one eye once daily for 7 days.

AGN-210961 Formulation 3drug

AGN-210961 Formulation 3 in one eye once daily for 7 days.

AGN-210961 Formulation 4drug

AGN-210961 Formulation 4 in one eye once daily for 7 days.

AGN-210961 Formulation 5drug

AGN-210961 Formulation 5 in one eye once daily for 7 days.

AGN-210961 Formulation 6drug

AGN-210961 Formulation 6 in one eye once daily for 7 days.

AGN-210961 Formulation 7drug

AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.

bimatoprost ophthalmic solution 0.03%drug

bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.